Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Sulfonamides"" wg kryterium: Temat


Tytuł :
Biochemical responses of the freshwater microalga Dictyosphaerium sp. upon exposure to three sulfonamides.
Autorzy :
Chen S; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China.
Li J; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China.
Feng W; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China.
Yuan M; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China.
Zhang W; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China. Electronic address: .
Xu H; School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China.
Zheng X; Shanghai Aquatic Environmental Engineering Co., Ltd, Shanghai 200090, China.
Wang L; Centre for Research on Environmental Ecology and Fish Nutrient of the Ministry of Agriculture, Key Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai 201306, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of environmental sciences (China) [J Environ Sci (China)] 2020 Nov; Vol. 97, pp. 141-148. Date of Electronic Publication: 2020 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
Microalgae*
Sulfonamides*
Chlorophyll A ; Ecosystem ; Fresh Water
Czasopismo naukowe
Tytuł :
Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of α 7 nAChR.
Autorzy :
Papke RL; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.) .
Garai S; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.).
Stokes C; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.).
Horenstein NA; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.).
Zimmerman AD; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.).
Abboud KA; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.).
Thakur GA; Departments of Pharmacology and Therapeutics (R.L.P., C.S., A.D.Z.) and Chemistry (N.A.H., K.A.A.), University of Florida, Gainesville, Florida; and Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts (S.G., G.A.T.) .
Pokaż więcej
Źródło :
Molecular pharmacology [Mol Pharmacol] 2020 Oct; Vol. 98 (4), pp. 292-302. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Sulfonamides/*chemical synthesis
Sulfonamides/*pharmacology
Xenopus laevis/*genetics
alpha7 Nicotinic Acetylcholine Receptor/*chemistry
alpha7 Nicotinic Acetylcholine Receptor/*metabolism
Allosteric Regulation/drug effects ; Animals ; Animals, Genetically Modified ; Binding Sites ; Humans ; Models, Molecular ; Molecular Docking Simulation ; Molecular Structure ; Mutation ; Stereoisomerism ; Sulfonamides/chemistry ; Xenopus laevis/metabolism ; alpha7 Nicotinic Acetylcholine Receptor/genetics
Czasopismo naukowe
Tytuł :
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Autorzy :
DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Maiti A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rausch CR; Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naqvi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kadia TM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ohanian M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Issa GC; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Montalban-Bravo G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Short NJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yilmaz M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bose P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jabbour EJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Takahashi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Burger JA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kornblau SM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Thompson PA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Estrov Z; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Verstovsek S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ferrajoli A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Weirda WG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wang SA; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konoplev S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen Z; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pierce SA; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ning J; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qiao W; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andreeff M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Welch JS; Division of Hematology & Oncology, Washington University School of Medicine, St Louis, MO, USA.
Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Konopleva MY; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 Oct; Vol. 7 (10), pp. e724-e736. Date of Electronic Publication: 2020 Sep 05.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Sulfonamides/*therapeutic use
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
Autorzy :
Urakawa H; Department of Orthopaedic Surgery, Nagoya University, Nagoya, Japan.; Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.
Kawai A; Department of Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan.
Goto T; Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Hiraga H; Department of Orthopaedic Surgery, Hokkaido Cancer Center, Sapporo, Japan.
Ozaki T; Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Tsuchiya H; Department of Orthopaedic Surgery, Kanazawa University, Kanazawa, Japan.
Nakayama R; Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan.
Naka N; Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, Japan.
Matsumoto Y; Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Kobayashi E; Department of Musculoskeletal Oncology, National Cancer Center, Tokyo, Japan.
Okuma T; Department of Musculoskeletal Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Kunisada T; Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Ando M; Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan.
Ueda T; Department of Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Nishida Y; Department of Orthopaedic Surgery, Nagoya University, Nagoya, Japan.; Department of Rehabilitation, Nagoya University Hospital, Nagoya, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 Sep; Vol. 111 (9), pp. 3303-3312. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Angiogenesis Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Sarcoma/*drug therapy
Sarcoma/*pathology
Sulfonamides/*therapeutic use
Adolescent ; Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Sarcoma/therapy ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Autorzy :
Wei L; Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China; Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
Wang G; Peking University First Hospital, Beijing, China.
Alami NN; AbbVie, North Chicago, IL, USA.
Xie W; Center of Liver Diseases, Beijing Di Tan Hospital, Capital Medical University, Beijing, China.
Heo J; Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, South Korea.
Xie Q; Department of Infectious Diseases, Rui Jin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Zhang M; Shenyang Sixth People's Hospital, Shenyang, China.
Kim YJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Lim SG; National University Healthcare System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Fredrick LM; AbbVie, North Chicago, IL, USA.
Lu W; AbbVie, North Chicago, IL, USA.
Liu W; AbbVie, North Chicago, IL, USA.
Kalluri HV; AbbVie, North Chicago, IL, USA.
Krishnan P; AbbVie, North Chicago, IL, USA.
Tripathi R; AbbVie, North Chicago, IL, USA.
Mobashery N; AbbVie, North Chicago, IL, USA.
Burroughs M; AbbVie, North Chicago, IL, USA.
Asatryan A; AbbVie, North Chicago, IL, USA.
Jia J; Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Hou J; Department of Infectious Diseases and Hepatology Unit, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: .
Pokaż więcej
Źródło :
The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2020 Sep; Vol. 5 (9), pp. 839-849. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Benzimidazoles/*therapeutic use
Hepatitis C, Chronic/*drug therapy
Pyrrolidines/*therapeutic use
Quinoxalines/*therapeutic use
Sulfonamides/*therapeutic use
Adult ; Aged ; Antiviral Agents/administration & dosage ; Antiviral Agents/therapeutic use ; Asia/epidemiology ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Case-Control Studies ; Double-Blind Method ; Drug Combinations ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/epidemiology ; Humans ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/etiology ; Male ; Middle Aged ; Placebos/administration & dosage ; Prevalence ; Pyrrolidines/administration & dosage ; Pyrrolidines/adverse effects ; Quinoxalines/administration & dosage ; Quinoxalines/adverse effects ; Respiratory Tract Infections/chemically induced ; Respiratory Tract Infections/epidemiology ; Safety ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Sustained Virologic Response ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Isolation and characterization of a marine bacterium Vibrio diabolicus strain L2-2 capable of biotransforming sulfonamides.
Autorzy :
Wang Q; CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Research Centre for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; Shandong Key Laboratory of Coastal Environmental Processes, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Jiang Y; CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Research Centre for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China.
Wang H; CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Research Centre for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; Shandong Key Laboratory of Coastal Environmental Processes, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China.
Chang X; College of Environmental and Material Engineering, Yantai University, Yantai, 264005, China.
Lv M; CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Research Centre for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; Shandong Key Laboratory of Coastal Environmental Processes, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China. Electronic address: .
Chen L; CAS Key Laboratory of Coastal Environmental Processes and Ecological Remediation, Research Centre for Coastal Environmental Engineering and Technology, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; Shandong Key Laboratory of Coastal Environmental Processes, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, China; Center for Ocean Mega-Science, Chinese Academy of Sciences, Qingdao, 266071, China. Electronic address: .
Pokaż więcej
Źródło :
Environmental research [Environ Res] 2020 Sep; Vol. 188, pp. 109718. Date of Electronic Publication: 2020 May 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Seawater*
Sulfonamides*
Vibrio
SCR Organism :
Vibrio diabolicus
Czasopismo naukowe
Tytuł :
Venetoclax plus cytochrome P450 inhibitors without ramp-up strategy led to low risk of tumor lysis syndrome in acute myeloid leukemia.
Autorzy :
Cheng FM; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Tien JZ; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Chen TT; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Yeh SP; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
Lin CC; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan. .; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, 404, Taiwan. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 2193-2195. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Letter
MeSH Terms :
Bridged Bicyclo Compounds, Heterocyclic/*administration & dosage
Cytochrome P-450 Enzyme Inhibitors/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Sulfonamides/*administration & dosage
Tumor Lysis Syndrome/*prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azacitidine/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics ; Child ; Creatinine/blood ; Cytochrome P-450 Enzyme Inhibitors/adverse effects ; Cytochrome P-450 Enzyme Inhibitors/pharmacokinetics ; Drug Administration Schedule ; Drug Synergism ; Female ; Humans ; Hyperuricemia/chemically induced ; Hyperuricemia/drug therapy ; Leukemia, Myeloid, Acute/blood ; Male ; Middle Aged ; Retrospective Studies ; Sulfonamides/adverse effects ; Sulfonamides/pharmacokinetics ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Triazoles/pharmacokinetics ; Tumor Lysis Syndrome/etiology ; Urate Oxidase/therapeutic use ; Uric Acid/blood ; Young Adult
Opinia redakcyjna
Tytuł :
A novel indenone derivative selectively induces senescence in MDA-MB-231 (breast adenocarcinoma) cells.
Autorzy :
Priyanga J; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India.
Sharan Kumar B; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India.
Mahalakshmi R; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India.
Nirekshana K; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India.
Vinoth P; Department of Chemistry, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India.
Sridharan V; Department of Chemistry and Chemical Sciences, Central University of Jammu, Rahya-Suchani (Bagla), Samba, Jammu, India.
Bhakta-Guha D; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India. Electronic address: .
Guha G; Cellular Dyshomeostasis Laboratory, Department of Biotechnology, School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India. Electronic address: .
Pokaż więcej
Źródło :
Chemico-biological interactions [Chem Biol Interact] 2020 Nov 01; Vol. 331, pp. 109250. Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Cellular Senescence*/drug effects
Antineoplastic Agents/*chemical synthesis
Sulfonamides/*chemistry
Antineoplastic Agents/pharmacology ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Catalysis ; Cell Line, Tumor ; Cell Survival/drug effects ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; Down-Regulation/drug effects ; Female ; G1 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Palladium/chemistry ; Sulfonamides/chemical synthesis ; Survivin/metabolism ; Tumor Suppressor Protein p53/metabolism ; Up-Regulation/drug effects
Czasopismo naukowe
Tytuł :
Residue Monitoring and Risk Assessment of Cyazofamid and Its Metabolite in Korean Cabbage Under Greenhouse Conditions.
Autorzy :
Sarker A; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea.; Department of Soil Science, Faculty of Agriculture, EXIM Bank Agricultural University Bangladesh (EBAUB), Chapainawabganj, Bangladesh.
Lee SH; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea.
Kwak SY; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea.
Nam AJ; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea.
Kim HJ; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea.
Kim JE; School of Applied Biosciences, College of Agriculture and Life Sciences, Kyungpook National University, Daegu, 41566, Korea. .
Pokaż więcej
Źródło :
Bulletin of environmental contamination and toxicology [Bull Environ Contam Toxicol] 2020 Oct; Vol. 105 (4), pp. 595-601. Date of Electronic Publication: 2020 Aug 29.
Typ publikacji :
Journal Article
MeSH Terms :
Fungicides, Industrial/*toxicity
Imidazoles/*toxicity
Pesticide Residues/*toxicity
Sulfonamides/*toxicity
Brassica/chemistry ; Chromatography, Liquid/methods ; Fungicides, Industrial/chemistry ; Fungicides, Industrial/metabolism ; Half-Life ; Imidazoles/metabolism ; Pesticide Residues/analysis ; Pesticide Residues/metabolism ; Republic of Korea ; Risk Assessment ; Sulfonamides/metabolism
Czasopismo naukowe
Tytuł :
Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
Autorzy :
Vanderver A; Children's Hospital of Philadelphia, Philadelphia, PA .
Adang L; Children's Hospital of Philadelphia, Philadelphia, PA .
Gavazzi F; Children's Hospital of Philadelphia, Philadelphia, PA .
McDonald K; Children's Hospital of Philadelphia, Philadelphia, PA .
Helman G; Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.
Frank DB; Children's Hospital of Philadelphia, Philadelphia, PA.
Jaffe N; Children's Hospital of Philadelphia, Philadelphia, PA.
Yum SW; Children's Hospital of Philadelphia, Philadelphia, PA.
Collins A; Children's Hospital Colorado, Aurora, CO.
Keller SR; Children's Healthcare of Atlanta, Atlanta, GA.
Lebon P; Faculté de Médecine Université Paris Descartes, Paris, France.
Meritet JF; Hôpital Cochin, Paris, France.
Rhee J; Children's National Health System, Washington, DC.
Takanohashi A; Children's Hospital of Philadelphia, Philadelphia, PA.
Armangue T; Sant Joan de Déu Children's Hospital, Barcelona, Spain.
Ulrick N; Children's Hospital of Philadelphia, Philadelphia, PA.
Sherbini O; Children's Hospital of Philadelphia, Philadelphia, PA.
Koh J; Children's Hospital of Philadelphia, Philadelphia, PA.
Peer K; Children's Hospital of Philadelphia, Philadelphia, PA.
Besnier C; Children's Hospital of Philadelphia, Philadelphia, PA.
Scher C; Children's Hospital of Philadelphia, Philadelphia, PA.
Boyle K; Children's Hospital of Philadelphia, Philadelphia, PA.
Dubbs H; Children's Hospital of Philadelphia, Philadelphia, PA.
Kramer-Golinkoff J; Children's Hospital of Philadelphia, Philadelphia, PA.
Pizzino A; Children's Hospital of Philadelphia, Philadelphia, PA.
Woidill S; Children's Hospital of Philadelphia, Philadelphia, PA.
Shults J; University of Pennsylvania, Philadelphia, PA.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Sep 03; Vol. 383 (10), pp. 986-989.
Typ publikacji :
Clinical Trial; Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Autoimmune Diseases of the Nervous System/*drug therapy
Azetidines/*therapeutic use
Janus Kinase Inhibitors/*therapeutic use
Nervous System Malformations/*drug therapy
Sulfonamides/*therapeutic use
Adolescent ; Age of Onset ; Azetidines/adverse effects ; Biomarkers ; Child ; Child Development/drug effects ; Child, Preschool ; Dose-Response Relationship, Drug ; Female ; Gene Expression/drug effects ; Humans ; Infant ; Interferons/genetics ; Interferons/metabolism ; Janus Kinase Inhibitors/adverse effects ; Least-Squares Analysis ; Male ; Sulfonamides/adverse effects ; Young Adult
SCR Disease Name :
Aicardi-Goutieres syndrome
Raport
Tytuł :
Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Autorzy :
Romeo A; Department of Biology, Structural Bioinformatics Group, University of Rome Tor Vergata, Rome, Italy.
Iacovelli F; Department of Biology, Structural Bioinformatics Group, University of Rome Tor Vergata, Rome, Italy.
Falconi M; Department of Biology, Structural Bioinformatics Group, University of Rome Tor Vergata, Rome, Italy. Electronic address: .
Pokaż więcej
Źródło :
Virus research [Virus Res] 2020 Sep; Vol. 286, pp. 198068. Date of Electronic Publication: 2020 Jun 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*chemistry
Betacoronavirus/*chemistry
Heterocyclic Compounds, 4 or More Rings/*chemistry
Indoles/*chemistry
Perylene/*analogs & derivatives
Spike Glycoprotein, Coronavirus/*chemistry
Sulfonamides/*chemistry
Antiviral Agents/pharmacology ; Betacoronavirus/pathogenicity ; Binding Sites ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Gene Expression ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; High-Throughput Screening Assays ; Humans ; Indoles/pharmacology ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Pandemics ; Perylene/chemistry ; Perylene/pharmacology ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; Protein Multimerization ; Small Molecule Libraries/chemistry ; Small Molecule Libraries/pharmacology ; Spike Glycoprotein, Coronavirus/antagonists & inhibitors ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Sulfonamides/pharmacology ; Thermodynamics ; User-Computer Interface ; Virus Internalization/drug effects
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Does Canavalia ensiformis inoculation with Bradyrhizobium sp. enhance phytoremediation of sulfentrazone-contaminated soil?
Autorzy :
Mielke KC; Federal University of Viçosa, Department of Agronomy, Av. P.H. Rolfs, s/n, Viçosa, 36570-900, MG, Brazil. Electronic address: .
Bertuani RR; Federal University of Espiríto Santo, Department of Biological and Agriculture Science, Rodovia BR 101 Norte, Litoranêao s/n, São Mateus, 29932-540, ES, Brazil.
Pires FR; Federal University of Espiríto Santo, Department of Biological and Agriculture Science, Rodovia BR 101 Norte, Litoranêao s/n, São Mateus, 29932-540, ES, Brazil.
Bueno Cotta AJ; Federal University of Espiríto Santo, Department of Natural Sciences, Rodovia BR 101 Norte, Litoranêao s/n, São Mateus, 29932-540, ES, Brazil.
Egreja Filho FB; Federal University of Minas Gerais, Departament of Chemistry, Institute of Exact Sciences, Belo Horizonte, 31270-901, MG, Brazil.
Madalão JC; Federal University of Viçosa, Department of Agronomy, Av. P.H. Rolfs, s/n, Viçosa, 36570-900, MG, Brazil.
Pokaż więcej
Źródło :
Chemosphere [Chemosphere] 2020 Sep; Vol. 255, pp. 127033. Date of Electronic Publication: 2020 May 10.
Typ publikacji :
Journal Article
MeSH Terms :
Soil Microbiology*
Bradyrhizobium/*growth & development
Canavalia/*growth & development
Herbicides/*analysis
Soil Pollutants/*analysis
Sulfonamides/*analysis
Triazoles/*analysis
Biodegradation, Environmental ; Herbicides/metabolism ; Soil/chemistry ; Soil Pollutants/metabolism ; Sulfonamides/metabolism ; Symbiosis ; Triazoles/metabolism
Czasopismo naukowe
Tytuł :
Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.
Autorzy :
Ting C; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.
Malloy R; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.
Knowles D; Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.
Pokaż więcej
Źródło :
Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2020 Sep; Vol. 25 (5), pp. 438-443. Date of Electronic Publication: 2020 Apr 29.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Academic Medical Centers*
Drug Dosage Calculations*
Anti-Arrhythmia Agents/*administration & dosage
Atrial Fibrillation/*drug therapy
Heart Rate/*drug effects
Phenethylamines/*administration & dosage
Sotalol/*administration & dosage
Sulfonamides/*administration & dosage
Aged ; Anti-Arrhythmia Agents/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/physiopathology ; Boston ; Drug Monitoring ; Female ; Humans ; Long QT Syndrome/chemically induced ; Long QT Syndrome/physiopathology ; Male ; Middle Aged ; Phenethylamines/adverse effects ; Practice Patterns, Physicians' ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Sotalol/adverse effects ; Sulfonamides/adverse effects ; Torsades de Pointes/chemically induced ; Torsades de Pointes/physiopathology
Czasopismo naukowe
Tytuł :
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Autorzy :
Zhang X; Department of Pharmacy, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.
Zhang Y; Research Department, Wuxi Maternal and Child Health Hospital Attached to Nanjing Medical University, Wuxi 214002, Jiangsu, China.
Qiao W; Center of Clinical Research, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.
Zhang J; Lung Transplant Center, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China.
Qi Z; Department of Pharmacy, Wuxi People's Hospital Attached to Nanjing Medical University, Wuxi 214023, Jiangsu, China. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2020 Sep; Vol. 86, pp. 106749. Date of Electronic Publication: 2020 Jul 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Azetidines/*therapeutic use
Betacoronavirus/*immunology
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Pneumonia, Viral/*drug therapy
Signal Transduction/*drug effects
Sulfonamides/*therapeutic use
Azetidines/pharmacology ; Betacoronavirus/metabolism ; Clinical Trials as Topic ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/immunology ; Cytokine Release Syndrome/diagnosis ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/virology ; Cytokines/immunology ; Cytokines/metabolism ; Humans ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 1/metabolism ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase 2/metabolism ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/immunology ; Severity of Illness Index ; Signal Transduction/immunology ; Sulfonamides/pharmacology ; Treatment Outcome ; Virus Assembly/drug effects ; Virus Internalization/drug effects
SCR Disease Name :
COVID-19
Czasopismo naukowe
Tytuł :
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Autorzy :
Eide CA; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Howard Hughes Medical Institute, Portland, OR, USA.
Kurtz SE; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Kaempf A; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Long N; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Agarwal A; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Tognon CE; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Howard Hughes Medical Institute, Portland, OR, USA.
Mori M; Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Portland State University and Oregon Health & Science University School of Public Health, Portland, OR, USA.
Druker BJ; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Howard Hughes Medical Institute, Portland, OR, USA.
Chang BH; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Danilov AV; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Tyner JW; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. .; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2020 Sep; Vol. 34 (9), pp. 2342-2353. Date of Electronic Publication: 2020 Feb 24.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Sulfonamides/*therapeutic use
Animals ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Cell Line, Tumor ; Humans ; Mice ; Sulfonamides/pharmacology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Autorzy :
Al-Sawaf O; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Zhang C; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Tandon M; Roche Products Limited, Welwyn Garden City, UK.
Sinha A; Roche Products Limited, Welwyn Garden City, UK.
Fink AM; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Robrecht S; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Samoylova O; Regional Clinical Hospital NA Semashko, Nizhny Novgorod, Russia.
Liberati AM; Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy.
Pinilla-Ibarz J; Department of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Opat S; Haematology Department, School of Clinical Sciences at Monash Health, Monash University, VIC, Australia.
Sivcheva L; First Internal Department, MHAT Hristo Botev, AD, Vratsa, Bulgaria.
Le Dû K; Hematology Department, Clinique Le Mans, France.
Fogliatto LM; Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Weinkove R; Wellington Blood and Cancer Centre, Capital and Coast District Health Board and Malaghan Institute of Medical Research, Wellington, New Zealand.
Robinson S; Queen Elizabeth II Health Science Center, Halifax, NS, Canada.
Kipps TJ; Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Tausch E; Department III of Internal Medicine, Ulm University, Ulm, Germany.
Schary W; AbbVie, North Chicago, IL, USA.
Ritgen M; Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.
Wendtner CM; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.
Kreuzer KA; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Eichhorst B; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Stilgenbauer S; Department III of Internal Medicine, Ulm University, Ulm, Germany.
Hallek M; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany. Electronic address: .
Fischer K; Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Sep; Vol. 21 (9), pp. 1188-1200.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*administration & dosage
Bridged Bicyclo Compounds, Heterocyclic/*administration & dosage
Chlorambucil/*administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Sulfonamides/*administration & dosage
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Chlorambucil/adverse effects ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Sulfonamides/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The remediation of sulfonamides from the environment by Pleurotus eryngii mycelium. Efficiency, products and mechanisms of mycodegradation.
Autorzy :
Baran W; Department of General and Analytical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska 4, 41-200, Sosnowiec, Poland.
Adamek E; Department of General and Analytical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Jagiellońska 4, 41-200, Sosnowiec, Poland. Electronic address: .
Włodarczyk A; Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland.
Lazur J; Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland.
Opoka W; Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland.
Muszyńska B; Department of Pharmaceutical Botany, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688, Kraków, Poland. Electronic address: .
Pokaż więcej
Źródło :
Chemosphere [Chemosphere] 2021 Jan; Vol. 262, pp. 128026. Date of Electronic Publication: 2020 Aug 22.
Typ publikacji :
Journal Article
MeSH Terms :
Models, Theoretical*
Environmental Pollutants/*analysis
Mycelium/*metabolism
Pleurotus/*metabolism
Sulfonamides/*analysis
Biodegradation, Environmental ; Biomass ; Carbohydrates/analysis ; Environmental Pollutants/metabolism ; Mycelium/growth & development ; Pleurotus/growth & development ; Sulfonamides/metabolism
Czasopismo naukowe
Tytuł :
Design, synthesis and biological evaluation of carbohydrate-based sulphonamide derivatives as topical antiglaucoma agents through selective inhibition of carbonic anhydrase II.
Autorzy :
Hou Z; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Li C; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Liu Y; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Zhang M; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Wang Y; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Fan Z; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Guo C; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Lin B; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Liu Y; Key Laboratory of Structure-Based Drugs Design and Discovery (Ministry of Education), School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 383-390.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antihypertensive Agents/*pharmacology
Carbohydrates/*pharmacology
Carbonic Anhydrase II/*antagonists & inhibitors
Carbonic Anhydrase Inhibitors/*pharmacology
Sulfonamides/*pharmacology
Animals ; Antihypertensive Agents/chemical synthesis ; Antihypertensive Agents/chemistry ; Carbohydrates/chemistry ; Carbonic Anhydrase II/metabolism ; Carbonic Anhydrase Inhibitors/chemical synthesis ; Carbonic Anhydrase Inhibitors/chemistry ; Cell Line ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Epithelial Cells ; Humans ; Hydrogen-Ion Concentration ; Molecular Docking Simulation ; Molecular Structure ; Rats ; Solubility ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry
Czasopismo naukowe
Tytuł :
Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells.
Autorzy :
Poole AT; Department of Chemistry, Brandon University, Brandon, Canada.
Sitko CA; Department of Chemistry, Brandon University, Brandon, Canada.
Le C; Department of Chemistry, Brandon University, Brandon, Canada.
Naus CC; Department of Cellular and Physiological Sciences, University of British Columbia, Life Science Institute, Vancouver, Canada.
Hill BM; Department of Chemistry, Brandon University, Brandon, Canada.
Bushnell EAC; Department of Chemistry, Brandon University, Brandon, Canada.
Chen VC; Department of Chemistry, Brandon University, Brandon, Canada.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 672-681.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Matrix Metalloproteinase 3/*metabolism
Matrix Metalloproteinase Inhibitors/*pharmacology
Sulfonamides/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Brain Neoplasms/metabolism ; Brain Neoplasms/pathology ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Glioblastoma/metabolism ; Glioblastoma/pathology ; Humans ; Matrix Metalloproteinase Inhibitors/chemical synthesis ; Matrix Metalloproteinase Inhibitors/chemistry ; Molecular Docking Simulation ; Molecular Structure ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
Autorzy :
Ruzzolini J; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Laurenzana A; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Andreucci E; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Peppicelli S; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Bianchini F; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Carta F; Department of NEUROFARBA, University of Florence, Florence, Italy.
Supuran CT; Department of NEUROFARBA, University of Florence, Florence, Italy.
Romanelli MN; Department of NEUROFARBA, University of Florence, Florence, Italy.
Nediani C; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Calorini L; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.; Center of Excellence for Research, Transfer and High Education, DenoTHE University of Florence, Florence, Italy.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 391-397.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Carbonic Anhydrase IX/*antagonists & inhibitors
Carbonic Anhydrase Inhibitors/*pharmacology
Histone Deacetylase Inhibitors/*pharmacology
Histone Deacetylases/*metabolism
Phenylurea Compounds/*pharmacology
Sulfonamides/*pharmacology
Antigens, Neoplasm/metabolism ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carbonic Anhydrase IX/metabolism ; Carbonic Anhydrase Inhibitors/chemical synthesis ; Carbonic Anhydrase Inhibitors/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Histone Deacetylase Inhibitors/chemical synthesis ; Histone Deacetylase Inhibitors/chemistry ; Humans ; Molecular Structure ; Phenylurea Compounds/chemical synthesis ; Phenylurea Compounds/chemistry ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry ; Tumor Cells, Cultured
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies